Can you describe the kinds of patients evaluated in the LEADER trial and, based on the results, what CV risk groups and clinical profiles with T2D would be most amenable to treatment with liraglutide?

Can you describe the kinds of patients evaluated in the LEADER trial and, based on the results, what CV risk groups and clinical profiles with T2D would be most amenable to treatment with liraglutide?

Can you describe the kinds of patients evaluated in the LEADER trial and, based on the results, what CV risk groups and clinical profiles with T2D would be most amenable to treatment with liraglutide?


Created by

CMEducation Resources IQ&A Interactive Intelligence Zone

Presenter

Juan Frias, FACE, MD

Juan Frias, FACE, MD

Clinical Assistant Professor of Medicine
University of California
San Diego, California
Chief Medical Officer
National Research Institute
Los Angeles, California